GlobeNewsWire
26 May 2026, 20:50 UTC · 2h ago
Source · https://www.globenewswire.com/news-release/2026/05/26/3301502/1087/en/INVESTOR-ALERT-Pomerantz-Law-Firm-Investigates-Claims-On-Behalf-of-Investors-of-Biogen-Inc-BIIB.html
Read source
Search tags
Story key points
2 claims · impact-rated
Biogen's Phase 2 CELIA study for diranersen (BIIB080) missed its primary dose-response endpoint. — Failure to meet primary endpoints in a clinical trial for a key Alzheimer's candidate significantly reduces the drug's probability of approval and future revenue.
-0.70Pomerantz LLP is investigating Biogen for potential securities fraud or unlawful business practices following the CELIA study results. — While common after stock drops, a formal investigation into corporate misconduct creates additional legal risk and potential liabilities for the company.
-0.30Impact vectors
3 dimensions · 9 clusters
Market reaction
0 bid · 10 offered
No stock impact ranking available yet.
Ticker attribution
Model heads
The company is facing a securities fraud investigation following a failed primary endpoint in a Phase 2 clinical study and a subsequent stock price drop.
The company is the subject of an investigation by Pomerantz LLP on behalf of investors.
The company is the subject of an investigation by Pomerantz LLP on behalf of investors.
No ticker relationship head found.
